Microspheres with high drug loading suitable for taste masking, enteric coatings, and extended release oral applications
Optimμm® technology overcomes many of the inefficiencies and deficits of traditional techniques. Optimμm® offers a wide range of modified release options using flexible format powders. It can match an extended release tablet’s performance in a suspension format. And with Optimμm® you don’t have to sacrifice taste to achieve a dispersed solid oral dosage form.
Optimμm® delivers on the promise of precision microparticles at a previously unachievable scale
- Dimensioni delle particelle fino a 75 μm con valori di Span fino a 0,40
- Utilizza un flusso "portante" di azoto
- Analogo alla rappresa a spruzzo
- Non è necessaria alcuna fase di asciugatura o rivestimento
- Compatible with waxes, lipids, stearates, and gelatins
- Ottimo per piccole molecole orali, nutraceutici, applicazioni agricole, aromi e molecole stabili al calore.
Parlare con un esperto
Nathan Dormer
Direttore, Sviluppo prodotti farmaceutici
Nathan Dormer, Ph.D., is the Director of Drug Product Development at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s Lenexa, KS site where he supports a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.
